NT_1170x120_1-11-18

lixisenatide

Sanofi cleared by FDA to market Adlyxin

Sanofi cleared by FDA to market Adlyxin

PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin